Case Reports in Hematology最新文献

筛选
英文 中文
Primary Cardiac Lymphoma Presenting with Thrombocytopenia, Right Heart Failure, and Cardiogenic Shock. 原发性心脏淋巴瘤表现为血小板减少、右心衰和心源性休克。
IF 0.7
Case Reports in Hematology Pub Date : 2023-01-01 DOI: 10.1155/2023/5501131
Samantha Kurniawan, Gita Mathur, Yvonne Bogun, Giselle Kidson-Gerber
{"title":"Primary Cardiac Lymphoma Presenting with Thrombocytopenia, Right Heart Failure, and Cardiogenic Shock.","authors":"Samantha Kurniawan,&nbsp;Gita Mathur,&nbsp;Yvonne Bogun,&nbsp;Giselle Kidson-Gerber","doi":"10.1155/2023/5501131","DOIUrl":"https://doi.org/10.1155/2023/5501131","url":null,"abstract":"<p><p>Primary cardiac lymphoma (PCL) is a rare, potentially fatal subtype of non-Hodgkin's lymphoma. Thrombocytopenia has also infrequently been reported in association with other primary cardiac tumours and can add substantial morbidity to an already life-threatening diagnosis if present. We report a rare case of a 70-year-old man who presented with thrombocytopenia (91 × 10<sup>9</sup>/L) and progressive right heart failure. Transthoracic echocardiogram revealed a large 8 × 4 cm right atrial mass with severe tricuspid obstruction, confirmed as PCL on subsequent endomyocardial biopsy and immunohistochemistry. He deteriorated into cardiogenic shock precipitated by atrial fibrillation, with worsening thrombocytopenia (18 × 10<sup>9</sup>/L) in the setting of ischaemic hepatitis. The patient stabilised with initiation of high dose steroids prior to tissue diagnosis and platelet counts normalised following chemotherapy. This case demonstrates the importance of considering PCL as a diagnosis and preemptive initiation of high dose steroids to improve outcomes in PCL associated with cardiogenic shock. This case also elucidates a potential pathophysiological association between PCL and thrombocytopenia.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2023 ","pages":"5501131"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9836803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10534004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation. 慢性髓系白血病中伊马替尼耐药与D363G BCR::ABL1激酶结构域突变相关
IF 0.7
Case Reports in Hematology Pub Date : 2023-01-01 DOI: 10.1155/2023/6673144
Stephen E Langabeer, Stuart Macleod, Úna Bhreathnach, Kamal Fadalla
{"title":"Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G <i>BCR::ABL1</i> Kinase Domain Mutation.","authors":"Stephen E Langabeer,&nbsp;Stuart Macleod,&nbsp;Úna Bhreathnach,&nbsp;Kamal Fadalla","doi":"10.1155/2023/6673144","DOIUrl":"https://doi.org/10.1155/2023/6673144","url":null,"abstract":"<p><p>Acquired resistance to tyrosine kinase inhibitors (TKIs) remains a therapeutic challenge in the treatment of chronic myeloid leukemia (CML). The most studied reason for TKI resistance is the acquisition of mutations within the <i>BCR::ABL1</i> tyrosine kinase domain (KDM) and of which the majority of which occur at seven codons within this region. A case of CML is described in which presence of a rare D363G <i>BCR::ABL1</i> KDM resulted in a suboptimal response to frontline imatinib. Switching to dasatinib resulted in achieving a sustained major molecular response that was maintained after a subsequent switch to bosutinib due to the side effects. Reporting of such cases is important for the future management of any CML patients with this rare mutation.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2023 ","pages":"6673144"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9761961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Rare Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Occurred in Postchemotherapy of Breast Cancer. 乳腺癌化疗后发生母浆细胞样树突状细胞肿瘤1例。
IF 0.7
Case Reports in Hematology Pub Date : 2023-01-01 DOI: 10.1155/2023/7573037
Jiankun Tong, Sergei Aksenov, Beth M Siegel, Lihong Wei, William H Rodgers
{"title":"A Rare Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Occurred in Postchemotherapy of Breast Cancer.","authors":"Jiankun Tong,&nbsp;Sergei Aksenov,&nbsp;Beth M Siegel,&nbsp;Lihong Wei,&nbsp;William H Rodgers","doi":"10.1155/2023/7573037","DOIUrl":"https://doi.org/10.1155/2023/7573037","url":null,"abstract":"<p><p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematologic malignancy that arises from plasmacytoid dendritic cells. BPDCN typically presents with skin lesions and may involve peripheral blood, bone marrow, lymph nodes, or extranodal sites. It usually arises de novo, and some BPDCN cases are associated with or develop into myeloid neoplasms. Here, we report a case of a 57-year-old female presenting with cervical lymphadenopathy and skin rashes during the COVID-19 pandemic in 2021 following multiple types of postmastectomy therapy for breast cancer. The patient was ultimately diagnosed with BPCDN by lymph node biopsy. To the best of our knowledge, this is the first case report of BPDCN occurring postchemotherapy of breast cancer.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2023 ","pages":"7573037"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344635/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9828979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Solitary Plasmacytoma of the Breast: A Case of an Uncommon Breast Neoplasm. 乳腺孤立性浆细胞瘤:一例罕见的乳腺肿瘤。
IF 0.7
Case Reports in Hematology Pub Date : 2023-01-01 DOI: 10.1155/2023/9622042
Sean McCormack, Eyad Hamad, Amar Hamad
{"title":"Solitary Plasmacytoma of the Breast: A Case of an Uncommon Breast Neoplasm.","authors":"Sean McCormack,&nbsp;Eyad Hamad,&nbsp;Amar Hamad","doi":"10.1155/2023/9622042","DOIUrl":"https://doi.org/10.1155/2023/9622042","url":null,"abstract":"<p><p>Plasmacytoma is a rare cancer that originates from a single plasma cell and is characterized by the abnormal proliferation of monoclonal plasma cells. It is typically localized in a single area of the body, most commonly in the bone or soft tissue. Solitary plasmacytoma can be further classified as either solitary plasmacytoma of bone (SPB) or solitary extramedullary plasmacytoma (SEP or EMP). Diagnosis may be delayed in symptomatically silent plasmacytomas, but early diagnosis and prompt treatment are crucial for the management of this disease. The mean age for patients with plasmacytoma varies depending on the specific type of plasmacytoma, but generally, it is more common in older adults. Soft tissue plasmacytomas are uncommon, and plasmacytomas manifesting within the breast are extremely rare, especially when they are not a manifestation of multiple myeloma (MM). This report presents a case of SEP of the breast in a 79-year-old female patient. This rare disease needs to be studied further in terms of long-term survival and disease progression to MM. By raising awareness and understanding of plasmacytoma, we aim to improve outcomes and quality of life for patients affected by this disease.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2023 ","pages":"9622042"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9620240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification. 含有t(11;14)和1q扩增的IgE浆细胞白血病。
IF 0.7
Case Reports in Hematology Pub Date : 2023-01-01 DOI: 10.1155/2023/4747989
Wataru Nakahara, Takahito Ogawa, Hitomi Matsunaga, Yuki Iwasa, Momoka Horita, Mako Ikeda, Mizuki Asako, Sadaharu Iio, Yuki Iwama, Kazumasa Oka, Shuji Ueda
{"title":"IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification.","authors":"Wataru Nakahara,&nbsp;Takahito Ogawa,&nbsp;Hitomi Matsunaga,&nbsp;Yuki Iwasa,&nbsp;Momoka Horita,&nbsp;Mako Ikeda,&nbsp;Mizuki Asako,&nbsp;Sadaharu Iio,&nbsp;Yuki Iwama,&nbsp;Kazumasa Oka,&nbsp;Shuji Ueda","doi":"10.1155/2023/4747989","DOIUrl":"https://doi.org/10.1155/2023/4747989","url":null,"abstract":"<p><p>IgE plasma cell neoplasm is the rarest subtype of plasma cell neoplasms and is known for its poor prognosis and high incidence of t(11;14). However, t(11;14) has been classified as a standard-risk rather than high-risk cytogenetic abnormality in multiple myeloma. We have been unable to explain the discrepancy that the hallmark of IgE plasma cell neoplasm with a poor prognosis is a standard-risk cytogenetic abnormality. Here, we report a case of IgE primary plasma cell leukemia with extramedullary lesions of the liver, stomach, and lymph nodes. Plasma cell infiltration was pathologically confirmed in each organ. Cytogenetic analysis of plasma cells revealed t(11;14) and amplification of 1q21. Chemotherapy, with immunomodulatory imide drugs, proteasome inhibitors, and CD38 antibodies, was unsuccessful. In IgE plasma cell neoplasm, coexistence of other cytogenetic abnormalities with t(11;14) may be important. Investigating the presence of cytogenetic abnormalities coexisting with t(11;14) is not only useful for evaluating prognosis but also important for understanding the pathogenesis of the disease. Recently, venetoclax, an oral BCL2 inhibitor, has demonstrated promising efficacy in plasma cell neoplasm patients harboring t(11;14). Development of an effective venetoclax-based regimen for treating aggressive IgE plasma cell neoplasm with t(11;14) is expected.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2023 ","pages":"4747989"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10162120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A Rare Case of Renal Thrombotic Microangiopathy and Focal Segmental Glomerulosclerosis Secondary to Plasma Cell Leukemia. 继发于浆细胞白血病的肾血栓性微血管病和局灶节段性肾小球硬化1例。
IF 0.7
Case Reports in Hematology Pub Date : 2023-01-01 DOI: 10.1155/2023/7803704
Justin Komisarof, Jessica Forman, Bruce Goldman, Chauncey Syposs, Frank Passero, Ellie Garbade
{"title":"A Rare Case of Renal Thrombotic Microangiopathy and Focal Segmental Glomerulosclerosis Secondary to Plasma Cell Leukemia.","authors":"Justin Komisarof,&nbsp;Jessica Forman,&nbsp;Bruce Goldman,&nbsp;Chauncey Syposs,&nbsp;Frank Passero,&nbsp;Ellie Garbade","doi":"10.1155/2023/7803704","DOIUrl":"https://doi.org/10.1155/2023/7803704","url":null,"abstract":"<p><p>Plasma cell dyscrasias are a subset of hematological malignancies involving the production of monoclonal immunoglobulins. This spectrum of disorders includes asymptomatic conditions such as monoclonal gammopathy of unknown significance as well as extremely aggressive malignancies such as plasma cell leukemia. Monoclonal gammopathies are occasionally associated with renal failure, which can occur via many pathophysiological processes. The most common of these is light chain cast nephropathy, but many rare renal complications exist, including thrombotic microangiopathy (TMA) and focal segmental glomerulosclerosis (FSGS). Here, we report a patient with new renal failure with features of TMA and FSGS on biopsy and found to be secondary to plasma cell leukemia.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2023 ","pages":"7803704"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10813965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Mixed Warm/Cold Autoimmune Hemolytic Anemia: A Case Report and Review of Current Literature. 温冷混合型自身免疫性溶血性贫血的治疗:1例报告及文献回顾
IF 0.7
Case Reports in Hematology Pub Date : 2023-01-01 DOI: 10.1155/2023/1381861
Elliot C Smith, Nabeel Kahwash, Siavash Piran
{"title":"Management of Mixed Warm/Cold Autoimmune Hemolytic Anemia: A Case Report and Review of Current Literature.","authors":"Elliot C Smith,&nbsp;Nabeel Kahwash,&nbsp;Siavash Piran","doi":"10.1155/2023/1381861","DOIUrl":"https://doi.org/10.1155/2023/1381861","url":null,"abstract":"<p><strong>Background: </strong>Mixed warm/cold autoimmune hemolytic anemia (AIHA) is a rare diagnostic entity with limited therapeutic options. Previous literature has described the diagnostic difficulty in this pathology and the limited response rates to corticosteroids. Furthermore, there is limited evidence regarding the use of rituximab in this condition.</p><p><strong>Methods: </strong>Alongside our case report, we conducted a scoping review of case reports/case series describing mixed AIHA, their treatment, and clinical outcomes since 2000. Inclusion criteria included a confirmed diagnosis of mixed AIHA (confirmed warm antibodies and cold agglutinins based on DAT). <i>Case Summary/Results</i>. We present a case of mixed AIHA in an 83-year-old female presenting with extensive, bilateral pulmonary embolisms and left renal vein thrombosis. The patient underwent extensive workup with no identifiable provoking etiology. Initial treatment involved prednisone therapy was transitioned to rituximab upon diagnosis of mixed AIHA. The patient demonstrated a mixed response with stable hemoglobin and transfusion independence; however, with persistently elevated hemolytic indices following completion of rituximab treatment. Our literature review identified 16 articles; two were excluded for unavailable clinical details. The most commonly associated conditions included autoimmune conditions (<i>n</i> = 5, 26%) and lymphoproliferative disorders (<i>n</i> = 3, 12%). The most common treatment involved corticosteroids; seven studies involved the use of rituximab.</p><p><strong>Conclusion: </strong>Mixed AIHA represents a complex diagnosis and optimal management is not well established. Consistent with our case, recent literature suggests a promising response to rituximab and a limited response to steroid treatment. Given the limited literature, additional studies are required to elucidate optimal management of this unique pathology.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2023 ","pages":"1381861"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9928731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Case Report of Premalignant Plasma Cell Dyscrasia-Induced Renal Failure in a 31-Year-Old Female 31岁女性癌前浆细胞病变致肾功能衰竭1例报告
IF 0.7
Case Reports in Hematology Pub Date : 2022-06-07 DOI: 10.1155/2022/2497380
Ayrton I Bangolo, MA Akhter, Amer Jarri, Manpreet Kaur, Ali Atoot, Parul Jandir, Mahmood Ibrahim, Lochana Manandhar, A. Atoot
{"title":"A Case Report of Premalignant Plasma Cell Dyscrasia-Induced Renal Failure in a 31-Year-Old Female","authors":"Ayrton I Bangolo, MA Akhter, Amer Jarri, Manpreet Kaur, Ali Atoot, Parul Jandir, Mahmood Ibrahim, Lochana Manandhar, A. Atoot","doi":"10.1155/2022/2497380","DOIUrl":"https://doi.org/10.1155/2022/2497380","url":null,"abstract":"Monoclonal gammopathy of renal significance (MGRS) is a rare disorder in which monoclonal immunoglobulin secreted by nonmalignant B cell or plasma cell clone causes kidney damage. Although MGRS is a premalignant condition, it can cause severe kidney disease and end-stage renal disease (ESRD) at any age. Herein, we present a 31-year-old female with past medical history of lupus nephritis who presented with signs of volume overload and worsening renal function despite adequate immunosuppressive therapy. Renal biopsy revealed heavy and light chain deposition consistent with MGRS. This case report demonstrates the importance of including MGRS in the differential diagnosis of worsening renal function despite adequate treatment, raising awareness of this premalignant yet morbid condition.","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"38 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2022-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81162392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Transient Complete Recovery of Chronic Refractory Idiopathic Thrombocytopenic Purpura after Treatment with Monoclonal Antibody Targeting SARS-CoV-2 Spike Protein 靶向SARS-CoV-2刺突蛋白单克隆抗体治疗慢性难治性特发性血小板减少性紫癜后的短暂完全恢复
IF 0.7
Case Reports in Hematology Pub Date : 2022-06-07 DOI: 10.1155/2022/8335541
Pooja Gogia, Yiqing Xu
{"title":"Transient Complete Recovery of Chronic Refractory Idiopathic Thrombocytopenic Purpura after Treatment with Monoclonal Antibody Targeting SARS-CoV-2 Spike Protein","authors":"Pooja Gogia, Yiqing Xu","doi":"10.1155/2022/8335541","DOIUrl":"https://doi.org/10.1155/2022/8335541","url":null,"abstract":"Idiopathic thrombocytopenic purpura (ITP), also known as immune thrombocytopenic purpura, is an immune-mediated acquired disease characterized by transient or persistent decrease of the platelet count due to autoimmune-related destruction of platelets. Therapy for ITP relies on competing and inhibiting the autoantibody binding and destruction (intravenous immunoglobulin and anti-D immunoglobulin and spleen tyrosine kinase (Syk) inhibitor fostamatinib), augmenting platelet production (thrombopoietin receptor agonists), immunosuppression to reduce the autoantibody production, as well as splenectomy. Studies on autoantigens on the platelets suggested epitopes to be located predominantly on the GP IIb/IIIa receptor or integrin αIIbβ3, though the trigger for the development of ITP is unclear. We report a case here of a 37-year-old gentleman who has chronic ITP managed on eltrombopag, who after receiving monoclonal antibody against SARS-CoV-2 (mAb) i.e. casirivimab and imdevimab for his COVID-19 infection, demonstrated complete recovery of his platelet count for a short period of time. We discuss a few potential mechanisms of action and propose further studies to elucidate the therapeutic effect of COVID-19 mAb in ITP.","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"3 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2022-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78294529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Rare Case of Extensive Cerebral Venous Sinus Thrombosis Complicated by Heparin-Induced Thrombocytopenia 广泛脑静脉窦血栓形成并发肝素性血小板减少症1例
IF 0.7
Case Reports in Hematology Pub Date : 2022-06-06 DOI: 10.1155/2022/7845786
Noman Ahmed Jang Khan, A. Farooqi, Mohamed Alsharedi
{"title":"A Rare Case of Extensive Cerebral Venous Sinus Thrombosis Complicated by Heparin-Induced Thrombocytopenia","authors":"Noman Ahmed Jang Khan, A. Farooqi, Mohamed Alsharedi","doi":"10.1155/2022/7845786","DOIUrl":"https://doi.org/10.1155/2022/7845786","url":null,"abstract":"Cerebral venous sinus thrombosis (CVST) is a rare but potentially life-threatening cause of stroke. Several risk factors have been identified including hypercoagulable state, malignancy, use of oral contraceptives, pregnancy, head injury, infection, and prothrombotic states such as heparin-induced thrombocytopenia (HIT). HIT is a prothrombotic state leading to thrombosis in several distinct locations including CVST requiring prompt discontinuation of heparin and initiation of nonheparin anticoagulation to prevent catastrophic consequences. Very rarely, HIT can complicate the ongoing CVST leading to worsening thrombosis and clinical deterioration. We here report an exceedingly rare case of CVST complicated by HIT in a 22-year-old female patient who showed remarkable clinical improvement after discontinuation of heparin and initiation of argatroban.","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"31 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2022-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86998734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信